Gujarat Themis Biosyn Ltd (GUJTHEM) is currently trading at 360.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gujarat Themis Biosyn Limited (GTBL) is an India‑based fermentation-led pharmaceutical manufacturer focused on fermentation-derived intermediates and APIs, producing Rifamycin S/O intermediates and recently commissioning a multi-purpose synthetic and fermentation API plant at Vapi to forward-integrate into finished APIs and formulations. GTBL is undergoing a strategic transformation driven by a major multiphase capex program and two acquisitions: MicroBiopharm Japan for advanced fermentation and biotech capabilities, and 13 Sanofi branded products across anti‑TB and anti‑infective segments giving GTBL commercial access to 55 countries and an immediate formulation distribution footprint. Financially, Q1 FY27 revenue was INR43.8 crore (up 22% YoY) with EBITDA of INR20.8 crore and a very high EBITDA margin of 47.5%, reflecting strong unit economics in current product lines and early benefits from higher volumes and product mix improvement as expanded capacity begins commercialization. Management projects accelerated commercialization of expanded fermentation and API capacity through FY27, expects high‑teen growth on a base case and is preparing funding via equity (up to INR1,000 crore QIP) plus multiple debt structures; near‑term risks include integration and regulatory timelines across multiple jurisdictions. Operational actions include commissioning a hybrid power project to reduce energy costs, running the new fermentation block at full scale, and transitioning Sanofi product manufacturing via a three‑year transition service agreement while pursuing API → formulation integration for margin capture.

Over the past 52 weeks, Gujarat Themis Biosyn Ltd has traded between a low of ₹225.75 and a high of ₹472.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gujarat Themis Biosyn Ltd has a market capitalization of approximately 4,878.74. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gujarat Themis Biosyn Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 100.22 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,878.74 Cr, Gujarat Themis Biosyn Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gujarat Themis Biosyn Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gujarat Themis Biosyn Ltd is 100.22. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

It issued an addendum to the AGM notice seeking shareholder approval for a special resolution to amend Article 119 of its Articles of Association.

Gujarat Themis Biosyn acquired a 100% equity stake in MicroBiopharm Japan Co., Ltd. (MBJ) through its wholly owned subsidiary, Themis Biosyn Japan Limited.

The board approved a preferential allotment of 82.11 lakh equity shares at ₹408 per share, aggregating to ₹335 crore, subject to shareholder and stock exchange approvals.

The company fixed the QIP issue price at ₹354 per equity share, including a premium of ₹353 per share over the ₹1 face value.